Optimer's Dificid linked to faster resolution of diarrhoea compared to vancomycin
This article was originally published in Scrip
Executive Summary
A new analysis of the Phase III results has shown that patients treated with its oral antibiotic Dificid (fidaxomicin) saw a speedier resolution of diarrhoea and lower risk of death during the first 12 days of initiation of treatment compared to those treated with ViroPharma's Vancocin (vancomycin). This boosts the company's marketing collateral for Dificid: Earlier this year Optimer gained US approval of Dificid for Clostridium difficile-associated diarrhoea, with superiority language differentiating the medicine from vancomycin, the only other US approved therapy for C. difficile (scripintelligence.com, 1 June 2011).